Theriva Biologics, Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount
Theriva Biologics, Inc. (TOVX) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount of $222.00 thousand for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-06.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpense · last filed 2025-03-06
- Theriva Biologics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2024 was $222.00K.
- Theriva Biologics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2023 was -$187.00K, a 132.52% decline from fiscal 2022.
- Theriva Biologics, Inc. effective income tax rate reconciliation, nondeductible expense, amount for fiscal 2022 was $575.00K.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Amount 12 month |
|---|---|
| 2024-12-31 | $222.00K 10-K · filed 2025-03-06 |
| 2023-12-31 | -$187.00K 10-K · filed 2025-03-06 |
| 2022-12-31 | $575.00K 10-K · filed 2024-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |